Karram S, Novy M, Saroufim M, Loya A, Taraif S, Houreih MA et al
Pfizer Key Development Products Berobenatide/PF3944, formerly MET-097i Long-acting GLP-1 receptor agonist MET-233i Amylin-related drug Combination of Berobenatide and MET-233i Oral small-molecule GLP-1 candidate Current Positioning Danuglipron, which was listed as a core development product in the previous edition, was discontinued in April 2025
Throughout this phase, we prioritise your comfort, ensuring that each step is clearly communicated and completed under the highest safety standards
Stability and Compatibility Stability remains a key consideration when formulating with copper peptides
10.1002/adhm.202401613 111
Animals received a systemic injection of amylin (5 g/kg), GLP-1 (100 g/kg), a combination of amylin and GLP-1 or vehicle